Selank vs. Semax is one of the most frequently compared pairings among peptides studied for their effects on brain function, cognitive abilities, stress resistance, and neuroprotection. Both synthetic peptides were developed in Russia and are widely analyzed for their potential impact on neurological functions, cognitive processes, and the body's adaptation to stress. Although they show some similarities, such as the possibility of nasal administration, potential neuroprotective properties, and interaction with signaling pathways in the brain, they were designed for different applications and possess distinct biological profiles. If you want to learn more about Selank, read our detailed guide: https://bioevidencehub.com/peptyd-selank/.
Semax was developed based on a fragment of adrenocorticotropic hormone (ACTH), while Selank is derived from the immunoregulatory peptide tuftsin and was modified by adding the Pro-Gly-Pro sequence, which increases its stability and prolongs its biological activity [1–4]. As a result, Semax is most often associated with supporting cognitive functions and neuroprotection, while Selank is primarily studied for regulating anxiety, stress resilience, and emotional balance.
Quick Comparison: Selank vs Semax
| Feature | Selank | Semax |
|---|---|---|
| Parent molecule | Taftsinah | ACTH(4-10) |
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Met-Glu-His-Phe-Pro-Gly-Pro |
| Main research area | Anxiety, stress resistance, emotion regulation | Cognitive functions, memory, neuroprotection |
| Key mechanisms | GABA modulation, enkephalinase inhibition, BDNF regulation | Dopamine and serotonin modulation, BDNF increase, neuroprotection |
| Studied effects | Anxiolytic, antistress, nootropic, immunomodulatory | Nootropic, neuroprotective, cognitive-enhancing |
| Clinical research areas | Generalized anxiety disorder, neurasthenia, anxiety states | Stroke recovery, cognitive impairments, cerebrovascular diseases |
| Nasal administration | Yes | Yes |
| BDNF Regulation | Yes | Yes |
| Sedative effect | Usually unobserved | Usually unobserved |
| The most common area of interest | Anxiety, stress management, emotional stability | Memory, concentration, learning, neuroprotection |
What is the main difference between Selank and Semax?
The biggest difference between Selank and Semax concerns their main area of research.
Selank has been primarily studied for its anxiolytic effects, stress resilience enhancement, emotion regulation, and promotion of a state of calmness. Research suggests it may influence GABA signaling, inhibit enzymes responsible for enkephalin breakdown, and regulate neurotrophic factors associated with mood and emotional processing [1–5].
Semax, on the other hand, has been more broadly analyzed for its effects on learning, memory, attention, cognitive performance, neuroprotection, and support for recovery after neurological damage. Experimental studies indicate that Semax may increase brain-derived neurotrophic factor (BDNF) levels, influence TrkB signaling, support neuron survival, and modulate dopamine and serotonin activity [6–12].
In simplified terms, Selank is often viewed as a „calming peptide,” while Semax is considered a „peptide that enhances concentration and cognitive functions.”.
Is Selank better than Semax for anxiety?
Based on available scientific research, Selank appears to have a stronger research basis in the context of anxiety-related applications.
Clinical trials involving patients suffering from generalized anxiety disorder (GAD) and neurasthenia have shown that Selank induces anxiolytic effects comparable to the benzodiazepine medazepam. Researchers also observed anti-asthenic effects and mild psychostimulant properties, allowing participants to maintain alertness and mental activity without many of the adverse effects characteristic of traditional anxiolytics [13].
Laboratory studies suggest that Selank acts as a positive allosteric modulator of GABA receptors, which may contribute to its anxiolytic effects. Additionally, it has been shown to inhibit enzymes responsible for the breakdown of endogenous enkephalins, potentially supporting stress resilience and emotional stability [2,3].
For researchers interested in the topics of anxiety, nervous tension, stress, or emotional regulation, Selank currently has a stronger scientific basis.
Is Semax Better Than Selank for Cognitive Function?
Semax has accumulated a larger number of studies concerning cognitive function, memory, attention, learning, and neuroprotection.
Experimental studies have shown that Semax can increase BDNF expression, improve hippocampal signaling, support learning and memory processes, protect neurons from ischemic damage, and affect dopaminergic and serotonergic pathways [6–10].
Semax has also been studied in post-stroke rehabilitation, where improvements in neurological recovery and functional treatment outcomes were observed. Additional research suggests that it regulates genes associated with inflammatory processes, immune response, blood vessel function, and neuron repair after brain injuries [8–12].
Due to this broader scope of research into cognitive functions, Semax is generally considered a peptide more targeted towards supporting cognitive processes.
How do Selank and Semax Affect the Brain?
Both peptides affect neuroplasticity and neuronal communication, however, they utilize partially different biological mechanisms.
Selank appears to regulate GABA receptor activity, influence BDNF expression, inhibit enkephalin degradation, and modify the expression of genes related to neurotransmission and immune system function. These mechanisms may account for its anxiolytic, stress-resistance supporting, and cognitive-enhancing effects [2–5,14].
Semax, on the other hand, shows a stronger influence on dopaminergic, serotonergic, neurotrophic, and neuroprotective pathways. Studies suggest that it increases BDNF production, enhances TrkB signaling, regulates inflammatory responses, and supports neuron survival after neurological damage [6–12].
Although both peptides can support brain health, they seem to focus on different aspects of neurological function.
Can Selank and Semax Be Used Together?
Selank and Semax are often discussed together because they act on complementary systems within the brain.
The theoretical justification for such a combination is relatively simple. Semax can support attention, memory, learning, and neuroprotection, while Selank can help regulate stress, anxiety, and emotions. As a result, both peptides could support both cognitive performance and mental resilience.
However, it should be emphasized that controlled clinical trials evaluating the concurrent use of Selank and Semax are currently very limited. For this reason, there is insufficient scientific evidence to determine whether the combination of both peptides provides better effects than the use of each one separately.
Which is better: Selank or Semax?
None of these peptides are objectively „better” as they were developed for different research purposes.
If the main research focus is anxiety, stress adaptation, emotional balance, or anti-anxiety mechanisms, Selank currently has stronger scientific support.
However, if the focus is on memory, learning, concentration, neuroprotection, stroke recovery, or neuroplasticity, Semax has accumulated more scientific evidence.
Many researchers perceive these compounds as complementary peptides rather than direct competitors, as they affect different neurological and psychological processes.
What Reddit Users Are Saying About Selank and Semax
Discussions on Reddit and other online communities often refer to Selank as the „calm peptide” and Semax as the „focus peptide.”.
Users often describe Selank as supporting relaxation, emotional stability, and a reduction in perceived anxiety without a distinct sedative effect. Semax, on the other hand, is sometimes described as a substance that improves clarity of thought, concentration, motivation, and productivity.
However, it's important to remember that these are purely anecdotal accounts and should not be treated as equivalent to clinical evidence. Controlled scientific studies remain a much more reliable source of information.
Summary
Selank and Semax are among the best-researched neuroactive peptides developed in Russia, but they were created with different applications in mind. Selank is primarily studied for anxiety reduction, emotion regulation, and increasing stress resilience, while Semax is mainly analyzed in the context of improving cognitive function, memory, neuroprotection, and neurological regeneration.
Current knowledge suggests that Selank may be a better choice for research on anxiety and emotional balance, while Semax appears more suitable for research on memory, concentration, learning, and neuroplasticity. Rather than competing with each other, both peptides are often seen as complementary research tools affecting various aspects of brain function.
Disclaimer
This article is intended solely for educational and informational purposes. Selank and Semax are research peptides, and the scientific literature regarding their effects is constantly evolving. The information presented here is a summary of the results of laboratory, preclinical, and clinical studies and should not be interpreted as medical advice, a therapeutic recommendation, or confirmation of efficacy.
For research purposes only: The Selank and Semax products offered by Semax Polska are intended exclusively for laboratory and scientific research. They are not approved for human consumption or for medical, diagnostic, therapeutic, or preventive use. All research materials should be used in accordance with applicable laws and the guidelines of institutions conducting scientific research.
References
[1] Vyunova, Tatiana V., Lioudmila Andreeva, Konstantin Shevchenko, and Nikolay Myasoedov. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[2] Zozulya, A. A., Kost, N. V., Sokolov, O. Yu., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Yu. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[3] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Yu., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[4] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Ya., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[5] Andreeva, L. A., Nagaev, I. Yu., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Ya., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral Properties of Structural Fragments of the Peptide Selank. Doklady Biological Sciences, 431, 79–82. https://doi.org/10.1134/S0012496610020031
[6] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotonergic Brain Systems in Rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[7] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Y., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax Regulates BDNF and TrkB Expression in the Rat Hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[8] Dolotov, O. V., Karpenko, E. A., Seredenina, T. S., Inozemtseva, L. S., Levitskaya, N. G., Zolotarev, Y. A., Kamensky, A. A., Grivennikov, I. A., Engele, J., & Myasoedov, N. F. (2006). Semax Binds Specifically and Increases BDNF Protein Levels in Rat Basal Forebrain. Journal of Neurochemistry, 97(Suppl. 1), 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x
[9] Gusev, E. I., Martynov, M. Y., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The Efficacy of Semax in Patients at Different Stages of Ischemic Stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
[10] Medvedeva, E. V., Dmitrieva, V. G., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2017). Semax Regulates Expression of Immune Response Genes During Ischemic Brain Injury in Rats. Molecular Genetics and Genomics, 292(3), 635–653. https://doi.org/10.1007/s00438-017-1297-1
[11] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborska, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2014). The Peptide Semax Affects Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia. BMC Genomics, 15, 228. https://doi.org/10.1186/1471-2164-15-228
[12] Sudarkina, O. Y., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Remizova, J. A., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2021). Brain Protein Expression Profile Confirms the Protective Effect of Semax in Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
[13] Seredyuk, A. V., Levitskiy, G. N., Myasoedov, N. F., & Skvortsova, V. I. (2007). Clinical Evaluation of Semax in Motor Neuron Disease. S.S. Korsakov Journal of Neurology and Psychiatry, 107(4), 29–39. https://pubmed.ncbi.nlm.nih.gov/18379501/
[14] 2025. Combined Action of Benzodiazepine Tranquilizers and Peptide Anxiolytic Selank in BALB/c Mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783